DEFA14A: ZimVie to Be Acquired by ARCHIMED in $730 Million All-Cash Deal, Offering 99% Premium to Shareholders

ZimVie Inc. has entered into a definitive merger agreement to be acquired by an affiliate of ARCHIMED for $19.00 per share in cash, representing a significant premium for stockholders.

Summary

• ZimVie Inc. has signed an Agreement and Plan of Merger with Zamboni Parent Inc., an affiliate of ARCHIMED, and Zamboni MergerCo Inc.
• Under the agreement, MergerCo will merge into ZimVie, with ZimVie becoming a wholly-owned subsidiary of Parent.
• Each outstanding share of ZimVie common stock will be converted into the right to receive $19.00 in cash, without interest.
• The total enterprise value of the transaction is approximately $730 million.
• The per-share price of $19.00 represents a 99% premium to ZimVie's 90-day volume-weighted average price (VWAP) of $9.57.
• ZimVie's Board of Directors unanimously approved the transaction.
• Outstanding restricted stock units (RSUs), stock options (Options), and deferred stock units (DSUs) will vest in full and be converted into cash payments based on the $19.00 merger consideration.
• The transaction is subject to customary closing conditions, including approval by ZimVie's stockholders and applicable regulatory approvals (e.g., Hart-Scott-Rodino Antitrust Improvements Act of 1976, non-U.S. antitrust, and foreign direct investment approvals).
• The merger agreement includes a 'go-shop' period allowing ZimVie to solicit alternative acquisition proposals from third parties until August 29, 2025, with a potential extension to September 3, 2025, for 'Excluded Parties'.
• Following the 'go-shop' period, ZimVie will be subject to customary 'no-shop' restrictions, with exceptions for unsolicited 'Superior Proposals'.
• The transaction is not subject to a financing condition, as Parent has secured equity and debt financing commitments.
• Termination fees are specified: $20,251,575 payable by ZimVie under certain circumstances (e.g., if ZimVie terminates to enter a superior proposal), reduced to $10,125,785 if for an Excluded Party during the go-shop period/extension; $40,503,150 payable by Parent if it fails to consummate the merger when required.

Sentiment

Score: 9

Explanation: The sentiment is overwhelmingly positive due to the significant premium offered to shareholders (99% above recent VWAP) and the unanimous board approval. The 'go-shop' period also provides an opportunity for potentially even better offers. While standard merger risks exist, the immediate and substantial cash value for shareholders makes this a highly favorable announcement.

Positives

• The merger consideration of $19.00 per share represents a substantial 99% premium over ZimVie's 90-day volume-weighted average price of $9.57, providing significant value to shareholders.
• ZimVie's Board of Directors unanimously approved the transaction, indicating strong internal support for the deal.
• The transaction is not subject to a financing condition, as the acquirer has secured equity and debt financing commitments, reducing funding risk.
• The 'go-shop' period allows ZimVie to actively solicit and consider potentially superior acquisition proposals, maximizing shareholder value.
• The acquisition by ARCHIMED, a healthcare-focused investment firm, is expected to provide strategic and financial backing to expand ZimVie's dental technology globally.

Negatives

• The merger agreement includes termination fees that ZimVie would be required to pay under certain circumstances, which could be a financial burden if the deal falls through due to ZimVie's actions.
• The proposed transaction may divert management's attention from ZimVie's ongoing business operations.
• The announcement or pendency of the proposed transaction could affect ZimVie's ability to attract, motivate, or retain key executives and employees, and maintain relationships with customers, suppliers, and other business counterparties.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Failure to receive required approvals from ZimVie's stockholders on a timely basis or otherwise.
• The possibility that various conditions to the consummation of the proposed transaction may not be satisfied or waived, including failure to receive required regulatory approvals from governmental entities.
• The possibility that competing offers or acquisition proposals for ZimVie will be made.
• The occurrence of any event, change, or circumstance that could give rise to the termination of the definitive transaction agreement, including scenarios requiring ZimVie to pay a termination fee.
• Risks related to stockholder litigation in connection with the proposed transaction, including resulting expense or delay.
• Other general risks discussed in ZimVie's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

Future Outlook

The transaction is expected to close by year-end 2025, subject to stockholder and regulatory approvals. Upon completion, ZimVie will become a privately held company, and its shares will no longer be listed on the NASDAQ stock exchange.

Management Comments

• Vafa Jamali, Chairman of the Board and Chief Executive Officer of ZimVie, stated that the transaction 'marks a new chapter for ZimVie and underscores the value our team has built over the past several years,' and that 'Partnering with ARCHIMED will create value for our shareholders while providing the strategic and financial backing to expand our innovative dental technology to more patients globally.'
• Andr-Michel Ballester, Managing Partner at ARCHIMED, commented, 'Were excited to partner with ZimVie and its talented team. The company has strong fundamentals and compelling growth potential, and we look forward to supporting its next chapter.'

Industry Context

This acquisition highlights a trend of consolidation and private equity interest in specialized segments of the life sciences and medical technology industries, particularly within the dental implant market. ARCHIMED's exclusive focus on healthcare industries suggests a strategic move to leverage ZimVie's position as a global leader in dental tooth replacement and restoration, aiming to expand its innovative dental technology globally. This could indicate a belief in the long-term growth potential and stable cash flows within this niche, making it attractive for private investment.

Corporate Governance

Legal Proceedings

• The filing notes the risk of stockholder litigation in connection with the proposed transaction, including resulting expense or delay.
• ZimVie is required to provide prompt notice to Parent of any Transaction Litigation and allow Parent to participate in its defense and settlement, with ZimVie not settling without Parent's prior written consent.

Related Party Transactions

• The Company Disclosure Letter (Section 3.20) sets forth a list of all material contracts, transactions, arrangements, or understandings between ZimVie or its subsidiaries and any present executive officer or director, 5% beneficial owner, or their affiliates, excluding employment-related contracts and Company Plans.

Stakeholder Impact

• Shareholders: Will receive a significant cash premium of $19.00 per share, representing a 99% premium to the 90-day VWAP, which is highly beneficial.
• Employees: The transaction may affect ZimVie's ability to attract, motivate, or retain key executives and employees due to uncertainty or changes in corporate structure. Employee benefits are generally maintained for one year post-merger, and service with ZimVie will be recognized for Parent Plans.
• Customers and Suppliers: The announcement or pendency of the transaction could impact relationships with customers and suppliers, though ZimVie is expected to operate business as usual until closing.
• Management: Attention may be diverted from ongoing business operations due to the transaction. Existing directors and officers will be replaced by MergerCo's leadership post-closing, but will retain indemnification rights and D&O insurance.
• Creditors: Existing indebtedness of ZimVie or its subsidiaries may be prepaid or repaid in connection with the transaction, as part of the financing uses.

Next Steps

• ZimVie will prepare and file a preliminary proxy statement with the SEC.
• ZimVie will hold a stockholder meeting to obtain the Company Stockholder Approval.
• ZimVie will continue to operate business as usual, separately from ARCHIMED, until the closing.
• The parties will work to obtain all necessary regulatory approvals, including under the HSR Act and non-U.S. antitrust/foreign direct investment laws.
• ZimVie will engage in a 'go-shop' period until August 29, 2025, to solicit alternative acquisition proposals.
• Upon closing, ZimVie's shares will be de-listed from NASDAQ and de-registered under the Exchange Act.
• The transaction is expected to close by year-end 2025.

Key Dates

Recommendation

The recommendation is 'strong buy' for existing shareholders due to the substantial 99% premium offered over the recent trading price, providing an immediate and significant return on investment. For new investors, it represents a compelling arbitrage opportunity if the stock trades below the $19.00 offer price, assuming the deal closes as expected. The unanimous board approval and the absence of a financing condition further de-risk the transaction, making it highly attractive.

Keywords

ZimVie, ARCHIMED, Merger, Acquisition, Dental Implants, Life Sciences, Healthcare Investment, Cash Transaction, Premium, SEC Filing, Corporate Action, Go-Shop, Regulatory Approval, Stockholder Approval